Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010317
Filing Date
2025-05-14
Accepted
2025-05-14 16:45:31
Documents
78
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1348831
2 EX-31.1 ex31-1.htm EX-31.1 18033
3 EX-31.2 ex31-2.htm EX-31.2 18019
4 EX-32.1 ex32-1.htm EX-32.1 7381
5 EX-32.2 ex32-2.htm EX-32.2 7295
  Complete submission text file 0001641172-25-010317.txt   8582381

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cldi-20250331.xsd EX-101.SCH 72935
7 XBRL CALCULATION FILE cldi-20250331_cal.xml EX-101.CAL 72808
8 XBRL DEFINITION FILE cldi-20250331_def.xml EX-101.DEF 303159
9 XBRL LABEL FILE cldi-20250331_lab.xml EX-101.LAB 596683
10 XBRL PRESENTATION FILE cldi-20250331_pre.xml EX-101.PRE 442995
80 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1380425
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40789 | Film No.: 25946620
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)